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Aims The aim of this article is to explore the influence of region and race/ethnicity on the effects of empagliflozin in the





Of 3730 patients, 1353 (36.3%) were enrolled in Europe, 1286 (34.5%) in Latin America, 425 (11.4%) in North
America, and 493 (13.2%) in Asia; 2629 (70.5%) were White, 257 (6.9%) Black, and 672 (18.0%) Asian. Placebo
event rates (per 100 patient-years) for cardiovascular death or heart failure (HF) hospitalization varied by region
(Asia 27.7, North America 26.4, Latin America 21.4, and Europe 17.5) and race/ethnicity (Black 34.4, Asian 24.3,
and White 18.7); driven by differences in HF hospitalization. The ratio of total HF hospitalization to cardiovascular
death varied from 5.4 in Asia and 4.8 in North America to 2.1 in Europe; and from 4.8 in Black and 4.2 in Asian to
2.2 in White patients. Groups with the highest ratio had the greatest reduction in the primary outcome with empa-
gliflozin. Inclusion of outpatient worsening HF episodes added more events in Europe vs. other regions; enhanced
the placebo event rates in Europe vs. other regions; and increased the relative risk reduction with empagliflozin in
Europe from 6% to 26%.
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Conclusions There were notable differences in the placebo event rates for major HF events across diverse regions and race/
ethnic groups. The benefit of empagliflozin was most pronounced in groups with the highest ratio of HF hospital-
ization to cardiovascular death. Regional differences were attenuated when the definition of HF events was
expanded to include outpatient worsening HF events.
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Introduction
Regional and racial/ethnic differences in the incidence of and
outcomes related to heart failure (HF) have been reported in both
observational studies and global clinical trials.1 These regional and
ethnic differences may reflect differences in patient characteristics,
comorbidities, medical practice, and healthcare delivery.2–4
In the Empagliflozin Outcome Trial in Patients with Chronic Heart
Failure and a Reduced Ejection Fraction (EMPEROR-Reduced), we
previously reported regional and race/ethnicity-related differences in
the effect of empagliflozin on the risk of cardiovascular death and HF
hospitalization in patients with chronic HF and a reduced ejection
fraction, with and without diabetes.5 The treatment effect appeared
to be more pronounced in North America, Latin America, and Asia
(relative risk reduction of 30–50%) than in Europe (relative risk re-
duction of 6%). Black and Asian patients experienced a greater risk
reduction with empagliflozin than White patients (40% vs. 12%).5,6
In a meta-analysis of two trials of sodium–glucose co-transporter 2
(SGLT2) inhibitors in HF and a reduced ejection fraction, the regional
and race/ethnicity-related heterogeneity was still apparent.6
However, the definition of regions was based on arbitrary geograph-
ical groupings, and the contribution of differences in background
medications, healthcare systems, and medical practice to this hetero-
geneity remained unexplored.
In the present study, we provide an in-depth study of the regional
and racial/ethnic differences in the EMPEROR-Reduced trial, with a
Graphical Abstract
Effect of empagliflozin by region and race in EMPEROR-Reduced. Inclusion of outpatient events in the extended composite endpoint attenuated the be-
tween-region differences in the effect of empagliflozin seen in the primary outcome of EMPEROR-Reduced.
...................................................................................................................................................................................................
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.particular emphasis on the role of HF hospitalizations and outpatient
HF events in influencing estimates of the magnitude of the effect of
empagliflozin.
Methods
The EMPEROR-Reduced trial was a randomized, double-blind, paral-
lel-group, placebo-controlled, and event-driven study, whose design
has been described previously.5 Participants were men or women
with chronic HF [New York Heart Association (NYHA) functional
class II, III, or IV] with a left ventricular ejection fraction of <_40%.
Patients with an ejection fraction of <_30% were preferentially enrolled
by requiring those with a higher ejection fraction to have been hospi-
talized for HF within 12 months or to have markedly increased levels
of N-terminal prohormone B-type natriuretic peptide (NT-proBNP),
i.e. >_1000 or >_2500 pg/mL in those with an ejection fraction of
31–35% or 36–40%, respectively; these thresholds were doubled in
patients with atrial fibrillation. The Ethics Committee of each of the
520 sites in 20 countries approved the protocol, and all patients gave
written informed consent.
Randomization and endpoints
Patients were randomized double-blind (in a 1:1 ratio) to receive
placebo or empagliflozin 10 mg daily, in addition to their usual ther-
apy. The primary endpoint was the composite of adjudicated cardio-
vascular death and hospitalization for HF, analysed as a time-to-first
event. The first secondary outcome was the occurrence of all adjudi-
cated hospitalizations for HF (including first and recurrent events).
To capture out-of-hospital worsening HF events, we analysed an
extended composite outcome of the time-to-first cardiovascular
death, hospitalization for HF, urgent visits for worsening of HF
requiring intravenous therapy, and outpatient intensification of oral
diuretic therapy.7
Definitions of region and race/ethnicity
The countries participating in the EMPEROR-Reduced trial were pro-
spectively but arbitrarily grouped into regions: Latin America, North
America, Europe, Asia, and ‘Other’ (which included India and Australia).
Race/ethnicity was self-identified as White, Black, Asian, and ‘Other’ (na-
tive American, Hawaiian/Pacific Islander, and any subject who selected
more than one race/ethnicity category).
Statistical analysis
Baseline characteristics were compared between regions and race/eth-
nicity using ANOVA for continuous variables and chi-square test for
categorical variables. For time-to-first-event analyses, differences be-
tween the placebo and empagliflozin groups were assessed using a
Cox proportional hazards model, with pre-specified baseline covari-
ates of age, sex, geographic region, diabetes, left ventricular ejection
fraction, and estimated glomerular filtration rate, based on all random-
ized patients according to the intention-to-treat principle. For the ana-
lysis of total (first and recurrent) events, between-group differences
were assessed using a joint frailty model, with cardiovascular death as
a competing risk. For all efficacy measures, treatment-by-subgroup (re-
gion and race/ethnicity) interaction terms were included in the models
and the effect of empagliflozin was estimated for the corresponding
subgroups. All analyses were performed using SAS, version 9.4 (SAS
Institute, Cary, NC, USA).
Results
Distribution by region and race/ethnicity
Of the 3730 patients in the EMPEROR-Reduced trial, 1353 (36.3%)
were enrolled in Europe, 1286 (34.5%) in Latin America, 425 (11.4%)
in North America, 493 (13.2%) in Asia, and 173 (4.6%) from India and
Australia. Of these, 2629 (70.5%) were White; 257 (6.9%) were
Black; 672 (18.0%) were Asian; and 114 (3.1%) were classified as
‘Other’. As expected, most Asian patients were from Asia; Black
patients were primarily recruited in Latin America (n = 154) and
North America (n = 100), whereas White patients were primarily
enrolled in Europe (n = 1281), Latin America (n = 1026), and North
America (n = 301) (Table 1).
Patient characteristics by region and
race/ethnicity
When compared with other regions, patients from Europe and
North America were older, had worse NYHA functional class, a lon-
ger duration of HF, worse renal function and were more likely to
have coronary artery disease and atrial fibrillation, but had lower NT-
proBNP levels. Patients from North America were also most likely to
be receiving an angiotensin receptor–neprilysin inhibitor but were
least likely to be treated with a mineralocorticoid receptor antagonist
(Table 2). Patients in Asia were most likely to have been hospitalized
.................................................................................................................................................
....................................................................................................................................................................................................................
Table 1 Distribution of patients in EMPEROR-Reduced by region and race
Race Overall (n 5 3730) Region
North America Latin America Europe Asia Othera
White 2629 (70.5) 301 (70.8) 1026 (79.8) 1281 (94.7) 0 21 (12.1)
Black 257 (6.9) 100 (23.5) 154 (12.0) 3 (0.2) 0 0
Asian 672 (18.0) 17 (4.0) 4 (0.3) 8 (0.6) 493 (100) 150 (86.7)
Otherb 114 (3.0) 7 (1.6) 102 (7.9) 3 (0.2) 0 2 (1.2)
Missing 58 (1.6) 0 0 58 (4.3) 0 0
aOther region comprises India and Australia.
bOther race comprises native American, Hawaiian/Pacific Islander, and any subject who selected more than one race category.
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for HF within 12 months and were least likely to be treated with
inhibitors of the renin–angiotensin system, beta-blockers, mineralo-
corticoid receptor antagonists, or cardiac devices.
Compared with other race/ethnic groups, Black patients were the
youngest and had the highest prevalence of hypertension, but the
most preserved renal function. Asian and other race/ethnic group
patients had the lowest body mass index but the highest prevalence
of diabetes and the highest values for the Kansas City
Cardiomyopathy Questionnaire (Table 2).
Outcomes in the placebo group by region
and race/ethnicity
The placebo arm event rate (per 100 person-years) for the primary
outcome of cardiovascular death or HF hospitalization was highest in
Asia (27.7) and North America (26.4) and lowest in Europe (17.5)
(Table 3 and Graphical abstract). These regional differences were
driven by differences in the incidence of HF hospitalization, since
there were no meaningful differences among regions in the incidence
of cardiovascular death (Asia 7.7, North America 6.7, Latin America
9.1, and Europe 7.7 per 100 patient-years). Total HF hospitalizations
(per 100 patient-years) in the placebo arm were highest in Asia
(41.4) and North America (31.9), followed by Latin America (18.9),
and lowest in Europe (16.3). Thus, the rate ratio of total HF hospital-
izations to cardiovascular death was highest in Asia and North
America (5.4 and 4.8, respectively) and lowest in Europe (2.1).
The inclusion of outpatient worsening HF events added 93 add-
itional placebo events in Europe, 53 in Latin America, 46 in Asia, and
27 in North America to the time-to-first-event analysis. As a result,
the incidence of the extended composite outcome in the placebo
group in Europe became similar to Latin America (31.6 and 31.2 per
100 patient-years, respectively), but remained lower than in North
America and Asia (with 41.9 and 52.5 events per 100 patient-years,
respectively) (Table 3 and Graphical abstract).
The event rate (per 100 person-years) for the primary composite
outcome of cardiovascular death or HF hospitalization in the placebo
group was highest among Black patients (34.4) and lowest in White
patients (18.7) (Table 4 and Graphical abstract). These racial/ethnic dif-
ferences were driven by differences in total hospitalizations for HF,
with no meaningful differences among races/ethnicities in the inci-
dence of cardiovascular death (Black 7.6, Asian 8.0, and White 8.1).
The incidence of total HF hospitalizations (per 100 patient-years) in
the placebo arm was highest in Black and lowest in White patients
(36.3 and 17.6 per 100 patient-years, respectively). Accordingly, the
ratio of total HF hospitalizations to cardiovascular death was highest
in Black patients and lowest in White patients (4.8 and 2.2, respect-
ively). The extended composite outcome (which included both in-
patient and outpatient worsening HF events) remained highest
among Black patients and lowest in White patients (51.5 and 30.4 per
100 patient-years, respectively) (Table 4 and Graphical abstract).
Influence of region and race/ethnicity on
effect of empagliflozin
The magnitude of the effect of empagliflozin on the primary compos-
ite outcome and total hospitalizations for HF was most pronounced
in Asia (hazard ratios of 0.55 and 0.41, respectively); intermediate in
North America (hazard ratios of 0.69 and 0.71, respectively) and
Latin America (hazard ratios of 0.73 and 0.65, respectively); and least
pronounced in Europe (hazard ratios of 0.94 and 0.96, respectively).
The treatment-by-region interaction was P = 0.10 for the primary
outcome and was P = 0.055 for total hospitalizations for HF. In gen-
eral, the higher the ratio of HF hospitalization to cardiovascular
death, the greater the magnitude of the treatment effect of empagli-
flozin on the primary and first secondary outcome measures (Table
3).
When outpatient HF events were included in the extended com-
posite endpoint, the magnitude of the effect of empagliflozin was
amplified in Europe where outpatient events were most numerous
(the hazard ratio declined from 0.94 to 0.74), but the inclusion of out-
patient events did not influence the effect size in Latin America or
other regions, where outpatient events were less frequent (Table 3).
A region-by-treatment interaction was apparent, even when adjusting
for baseline covariates reflecting background therapy with drugs and
devices for HF or a recent history of an HF hospitalization (inter-
action P = 0.031).
The magnitude of the effect of empagliflozin on the primary com-
posite outcome and on total hospitalizations for HF was most pro-
nounced in Black patients (hazard ratios of 0.46 and 0.39,
respectively) and Asian patients (hazard ratios of 0.57 and 0.45, re-
spectively) and least pronounced in White patients (hazard ratios of
0.88 and 0.90, respectively). The treatment-by-race interaction was
P = 0.008 for the primary outcome, P = 0.002 for total hospitaliza-
tions for HF and 0.002 for the extended composite outcome (Table
4). Adjusting for baseline covariates reflecting background therapy
with drugs and devices for HF or a recent history of an HF hospital-
ization did not alter these interactions. Interestingly, the effect of
empagliflozin in Black patients was more pronounced than in White
patients in the two regions where meaningful numbers of both Black
and White patients were recruited (North America and Latin
America) (Supplementary material online, Figure S1). When out-
patient worsening HF events were included in the analysis, the effect
size for empagliflozin in White patients increased from 12% to 19%
relative risk reduction.
Discussion
Even though the inclusion and exclusion criteria in the EMPEROR-
Reduced trial were standardized, there were notable differences in
the clinical characteristics in patients who were recruited in different
regions and among patients from different racial and ethnic back-
grounds. These differences may be related to contrasts in medical
practice and healthcare access that may occur across different
regions (or even within the same city or country). Many of the pat-
terns that we observed in the EMPEROR-Reduced trial are very simi-
lar to patterns that have been noted in previous trials and registries.
We were not surprised to find that coronary artery disease (and cor-
onary artery interventions) was particularly common in patients
recruited in North America and Europe. Similarly, it is well-known
that hypertension is particularly prevalent in Black patients and that
atrial fibrillation is more common in White patients. Asian patients
are especially prone to diabetes and to coronary artery disease (the
prevalence of which was nearly as high as in Whites), despite a lower
body mass index. Neprilysin inhibitors are most frequently
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prescribed in North America (and less frequently prescribed in Latin
America and Asia), whereas mineralocorticoid receptor antagonists
are popular in Latin America. Heart failure device therapy was more
commonly utilized in North America and Europe than in Latin
America or Asia. Many of these differences reflect known associa-
tions of cardiovascular risk factors with specific racial groups. Other
patterns represent differences in the availability of healthcare resour-
ces, which encourage the utilization of expensive interventions in
regions that have substantial financial resources to devote to health-
care.8–14
Did these differences in clinical characteristics, medical and device
therapy yield differences in patient outcomes? The rate of total HF
hospitalizations was strikingly different across regions, being nearly
three-fold higher in Asia than in Europe. Specifically, when treated
with placebo, the rate of total HF hospitalization was 41.4 in Asia, but
only 16.3 in Europe, with intermediate rates in the other regions. The
difference in HF hospitalization rates in Asia and Europe was not
related to the severity of the underlying HF, since the values for ejec-
tion fraction and natriuretic peptides were similar in the two regions,
and patients recruited in Europe were more likely to have had class
III/IV HF at the start of the trial. Furthermore, the risk of cardiovascu-
lar death was identical in Europe and Asia, suggesting a similar severity
of the underlying disease at baseline. However, in a time-to-first-
event analysis, it is noteworthy that the inclusion of outpatient events
provided 62% additional worsening HF events to the primary out-
come in the placebo group in Europe as compared with only 35%
additional events in Latin America, 42% in North America, and 58%
in Asia. Thus, worsening HF was more likely to be treated as an out-
patient in Europe than in other regions.15,16 These findings suggest
that European physicians prefer to treat worsening HF as an out-
patient rather than in a hospitalized setting.7,12,17,18
Differences in the way that worsening HF events are managed in
different regions may influence estimates of the effect of a drug that
reduces the risk of worsening HF events. This is especially true if the
treatment effect is described using time-to-first-event methods that
are applied to composite endpoints; in such analyses, non-fatal events
take precedence over deaths. Empagliflozin reduces the risk of the
composite of hospitalization for HF or cardiovascular death, a benefit
that is determined primarily by its ability to reduce hospitalizations.
Therefore, in a time-to-first-event analysis, the effect of empagliflozin
would be expected to be greater in regions where the ratio of HF
hospitalizations to cardiovascular mortality is higher. The ratio of
total HF hospitalizations to cardiovascular death in the placebo group
was >4 in Asia and North America, and in these regions, empagliflo-
zin reduces the risk of the primary endpoint by 30–45%; in contrast,
the ratio of total HF hospitalizations to cardiovascular death was only
2 in Europe, where the risk reduction produced by empagliflozin was
5%. However, when outpatient events were included in the ana-
lysis, the ratio of worsening HF events to cardiovascular death
increased dramatically in Europe, and at the same time, the risk re-
duction by empagliflozin increased from5% to 26%. In contrast, an
increase in the estimate of the treatment effect was not seen in
regions where outpatient treatment of worsening HF events was un-
common. Therefore, the modest response to the effect of SGLT2 in-
hibition on cardiovascular death and HF hospitalization in Europe
appeared to be related to the exclusion of outpatient worsening HF
events from the analysis of the primary endpoint. Many of the
outpatient events in Europe were likely treated in a hospital setting in
other geographical regions.
The inclusion of outpatient worsening HF events narrowed, but
did not eliminate, the between-region differences in the effect of
empagliflozin on the primary endpoint of the EMPEROR-Reduced
trial. A region-by-treatment interaction persisted because Black
and Asian patients had a more pronounced response to empagli-
flozin (when compared with White patients), regardless of the re-
gion in which they were recruited. Intriguingly, as in the case of
region, the magnitude of the benefit of empagliflozin paralleled the
frequency of hospitalizations for HF. The placebo arm ratio of
total HF hospitalizations to cardiovascular death was 4.8 and 4.2
in Black and Asian patients, respectively, and in these racial
groups, empagliflozin reduced the risk of the primary endpoint by
40–55%; in contrast, the ratio of total HF hospitalizations to car-
diovascular death was only 2.2 in White patients, and in this co-
hort, the risk reduction produced by empagliflozin was 12%.
Importantly, the inclusion of outpatient worsening HF events
increased the magnitude of the treatment effect in White patients
to a 19% risk reduction (hazard ratio 0.81; 95% confidence inter-
val 0.71, 0.93), without a meaningful change in the risk reduction
in Black and Asian patients.
Our finding of a race-by-treatment interaction is intriguing, but it is
not clear that it represents a replicable finding. Racial groups are not
homogeneous and varied meaningfully with respect to baseline char-
acteristics, and it is likely that unmeasured confounders may have
contributed to the differences that we observed. A recently pub-
lished meta-analysis that focused on cardiovascular death (and not
HF hospitalizations) reported a greater effect size in trials with a
higher recruitment of patients from Asia, but this conclusion was
based on a small effect that was discerned by the application of meta-
regression methods to trials that often had zero events.19 Another
recent meta-analysis reported a greater effect of SGLT2 inhibitors in
Asian patients, but this study did not analyse HF hospitalizations in
the large-scale cardiovascular outcomes trials in type 2 diabetes.20 A
registry report has suggested a smaller treatment effect of SGLT2
inhibitors on HF hospitalizations in Asia than in North America, but
this study used observational methods without the protection of ran-
domization.21 Most importantly, other large-scale randomized trials
in patients with HF and patients with type 2 diabetes did not report
an attenuated effect of SGLT2 inhibitors in general or of empagliflozin
specifically in White patients.22–24 In the EMPA-REG OUTCOME
trial, the hazard ratios and 95% confidence intervals for the effect of
empagliflozin to reduce the risk of a first HF hospitalization were 0.67
(0.49, 0.92), 0.49 (0.18, 1.31), and 0.70 (0.37, 1.33) in White, Black,
and Asian patients, respectively (interaction P = 0.82). This lack of ex-
ternal validation in trials that are comparable in size and design to the
current study suggests that the race-by-treatment interaction found
in EMPEROR-Reduced may not represent a replicable finding, par-
ticularly given the multiplicity of comparisons performed in the cur-
rent trial.
These findings should be considered in the context of the primary
analyses of EMPEROR-Reduced showing robust benefits of empagli-
flozin on the primary endpoint in the entire study population. Specific
acknowledged limitations include our definition of regions based on
arbitrary geographical groupings and our analysis of race/ethnicity
based on the self-report of participants. Therefore, our results may
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not be replicable if different criteria were used to define these patient
subgroups. Certain subgroups (particularly those in categories
labelled as ‘other’) were small and exceptionally heterogeneous, and
thus, the estimates in these groups were necessarily imprecise. While
outpatient treatment intensification events were not independently
adjudicated, ascertainment of these events was prespecified and pro-
spectively collected in the case report form. In addition to the adjudi-
cation and characterization of hospitalizations for HF, at each
scheduled study visit, patients were prospectively asked about inter-
val events and about changes in the use of diuretics that reflected the
occurrence of worsening HF since the last visit. We performed mul-
tiple statistical tests, which may have increased the possibility of
chance findings. Finally, our analyses were not pre-planned, and thus,
we did not assess socioeconomic status, medical practice, or access
to healthcare, which represent potentially important but unmeasured
confounding variables.
Conclusions
We observed notable differences in the baseline characteristics, the
placebo event rates for major HF events and the treatment effect
estimates across the diverse regions and racial/ethnic groups that par-
ticipated in the EMPEROR-Reduced trial. The benefits of empagliflo-
zin were most pronounced in regions and racial/ethnic groups with
the highest ratios of HF hospitalization to cardiovascular death.
Differences among regions and among racial/ethnic groups in the ef-
fect size estimates were attenuated when the analyses captured both
outpatient and inpatient worsening HF events.
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